TABLE 4.

Clinical trials of Danshen products as supplementary interference in the regulation of ulcerative colitis (UC) (Lipophilic cluster).

Study design	Interventions	Approach, duration, dose, frequence of danshen treatment	Participants (T/C)	Amount	Information of patients n, m/f, age (year), course (year)	Clinical efficacy	Adverse events	Outcome measurements	References
RCT (random number table)	C:mesalazine T:mesalazine + Tanshinone capsule	p.o., 4w, 1g, tid	C:44< T:44	88	C: 26, 18, 45.88 ± 9.22, 7.21 ± 5.30 T: 24, 20, 44.56 ± 10.11, 8.06 ± 4.83	N	N	PLT, MPV, APTT, FIB, D-D, CRP, TF, TFPI	He, (2018)
RCT (random number table)	C:mesalazine T:mesalazine + Tanshinone capsule	p.o., 8w,1g, tid	C:35 T:35	70	C: 15, 20, 46.8 ± 7.1, 5.2 ± 2.1 T: 16, 19, 47.4 ± 6.2, 5.1 ± 2.3	N	N	CRP, TNF-α, IL-6, APTT, FIB, PLT, MPV, PAG, D-D	Xiong and Wang, (2016)

N, no information; RCT, random control trial; CRP, C-reactive protein; PLT, serum levels of platelet; FIB, plasma fibrinogen; MPV, mean platelet volume; p.o, per os; tid, three times daily; PAG, platelet aggregation; APTT, activation partial prothrombin time; FIB, fibrinogen; D-D, D-dimer; CRP, C-reactive protein.; m: male; f:female; T: danshen treatment; C:conventional treatment.